Senseonics Launches New Patient Access Program in the U.S.

Published on
By : dLife Editors

Senseonics Holdings, Inc., a medical technology company developing a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of a new patient program.

Under the new the Eversense Bridge Program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for $99* plus the cost of the sensor placement by the healthcare provider.

“The Eversense Bridge Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” said Tim Goodnow, president, and CEO of Senseonics in a statement.

He adds insurance companies unfamiliar with the newest approved diabetes technology may deny coverage for a wide range of insured patients who have come forward demanding this technology.

“We developed this program to reduce barriers for patients who seek access to this technology right away,” Goodnow said. “Every patient who qualifies for the program will now have improved access to this innovative diabetes management technology.”

The Eversense Bridge Program is a patient access program designed to assist patients with confirming their insurance benefits, obtaining pre-authorizations before the sensor placement and working with their healthcare provider’s office to help patients with the appeals of denied claims.

“I commend Senseonics for addressing the critical issue of access barriers to new medical technology,” commented Amy TenderichDiabetesMine writer and diabetes advocate. “Diabetes equipment and supplies are very expensive for patients, often even with insurance coverage.”

What is the Eversense CGM System?

The Eversense CGM System is a unique alternative for continuous monitoring of glucose. It consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends, and alerts.

Unlike traditional CGMs, Eversense is the first and only implantable CGM sensor in the U.S. and has the longest duration of up to 90 days.

It features a smart transmitter that provides discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

Patients who are interested in getting started on Eversense through the Eversense Bridge Program can sign up at

Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact Senseonics at 844-SENSE4U (844-736-7348).

* For more details, see the full company press release.

Featured image courtesy: Senseonics Holdings, Inc.


  1. Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S. (2019, March 22). BusinessWire. Retrieved: